Accéder au contenu principal

HFpEF-DIVA

AIMS

Our aims are to:

I) Characterize pro-inflammatory mechanisms linking AF and HFpEF progression; in order to II) Guide Personalized Medicine for anti-cytokine treatments; and to III) Develop innovative nanomedicine tools blocking cytokine combinations.

Clinical investigations in blood monocytes will be performed in HFpEF patients, with or without AF, to define pro-inflammatory signatures associated with poor prognosis. In parallel, experimental investigations, using complementary HFpEF models, will determine the role of IL6, IL1β and the inflammasome in driving cardiac dysfunction. In addition to using cytokine-neutralizing antibodies as potential therapies in our animal models, we will investigate innovative multivalent therapeutic single-domain antibodies (VHH) for targeting of pro-inflammatory and pro-fibrotic cytokine combinations.

The ultimate goal of HFpEF-DIVA is to enable and direct Personalized Medicine to better treat individual patients by tailoring the therapy to their respective cardiovascular inflammatory profiles to limit HFpEF.